C
Cyclopharm Ltd
ASX:CYC
Cyclopharm Ltd
ASX:CYC
Price:
1.67 AUD
-1.76%
Market Closed
Updated:
May 14, 2024
EV/S
Enterprise Value to Sales
Enterprise Value to Sales
5.4
Current
6.3
Median
2.5
Industry
Lower
than median
Higher
than industry value
Enterprise Value to Sales (EV/S) ratio is a valuation multiple that compares the enterprise value (EV) of a company to its revenues. The EV/S multiple gives investors a quantifiable metric of how to value a company based on its sales while taking account of both the company's equity and debt.
EV/S
=5.4
Enterprise Value
/
149.4m
Revenue
27.8m
All Countries
| Market Cap | EV/S | ||||
|---|---|---|---|---|---|
| AU |
C
|
Cyclopharm Ltd
ASX:CYC
|
157.1m AUD | 5.4 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
180.9B USD | 4.6 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
136.3B USD | 17.8 | |
| US |
|
Stryker Corp
NYSE:SYK
|
123.5B USD | 6.3 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
111.9B USD | 4 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
107.9B USD | 7.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
67.9B USD | 4.1 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
59.2B EUR | 3.2 | |
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
375.2B CNY | 9.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
51.9B USD | 8.2 | |
| US |
|
Dexcom Inc
NASDAQ:DXCM
|
49.7B USD | 12.9 |
EV/S Forward Multiples
Forward EV/S multiple is a version of the EV/S ratio that uses forecasted revenue for the EV/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/S
4
2-Years Forward
EV/S
2.4
3-Years Forward
EV/S
1.8
You don't have any saved screeners yet
